New research highlights vast undertreatments and high levels of anxiety in psoriasis patients

(MADRID, 11 October, 2019) A striking proportion of psoriasis patients remain untreated with an average diagnosis time of five years, a new study has found.

The research, presented today at the 28th EADV Congress, analysed 650 psoriasis patients in Germany and identified major gaps in the provision of psoriasis care and how the disease affects day-to-day patient life.

Over half of patients (56%) with more than 20% of body surface area being covered by psoriasis expressed that they are not currently visiting a physician to help with the treatment of their condition, indicating that doctors invest too little time into patients, are not interested in the disease and are not well informed. Half of those prescribed drugs communicated that they do not help treat their condition (49%) or have too many side effects (29%).

Almost 9 in ten of the patients in the study suffered from plaques (patches of rough, red skin that are caused by skin cells reproducing too quickly), with the head and elbows being the most commonly affected areas. The condition is reported to have greater severity and greater impact on quality of life measures when it affects the anal and genital regions.

Psoriasis is a common, noncommunicable skin disease with at least 100 million individuals affected worldwide. The cause of psoriasis is currently unknown, but research shows that the immune system and genetics play a major part in the development of the condition.

“Despite psoriasis being a well-known disease, a striking proportion of patients remain undertreated”, commented lead researcher Maximilian Schielein. “Taking more time and finding an appropriate treatment for unsatisfied patients must be addressed to fulfil their needs. In addition, we must not neglect the patients who are dissatisfied with their current treatment and have given up seeking professional help. Reaching out to these patients is essential and healthcare professionals have a duty of care to ensure that everyone with psoriasis receives optimal care.”

Anxiety in psoriasis patients

A further study, also presented at the 28th EADV Congress, has shown that over three quarters (77%) of acute stage psoriasis patients had anxiety disorders, compared to 19% of the general population. When evaluating the degree of anxiety in psoriasis patients, the research found:

- 33% had high levels of anxiety
- 44% had average levels of anxiety
- 23% had lower levels of anxiety
The findings highlighted the need for interdisciplinary programmes for the diagnosis and treatment of psoriasis, as well as the inclusion of specific psychosocial interventions in the overall treatment regimen to help improve the course of the disease and long-term prognosis.

ENDS

Notes to Editors
A reference to the 28th EADV Congress must be included when communicating any information within this press release.

Contact:
For further information or to arrange an expert interview, please contact either:

Phoebe Deans – EADV Press Officer
phoebe@spinkhealth.com
+44 (0) 7732 499170

Jamie Wilkes – EADV Press Officer
jamie@spinkhealth.com
+44 (0) 7732 499170

Luke Paskins – EADV Press Officer
luke@spinkhealth.com
+44 (0) 1444 811099

About Maximilian Schielein, MPH:
Maximilian Schielein is from the Department of Dermatology and Allergy, Technical University of Munich, Germany.

About EADV:
Founded in 1987, EADV is a non-profit organisation whose vision is to be the premier European Dermato-Venereology Society. The Academy counts over 7,000 members from 100 countries, providing a valuable service for every type of dermato-venereologist professional. EADV are dedicated to advancing patient care, education and research by providing a unique platform to bring people together and share ideas.

The EADV Congress takes place every year and attracts over 13,000 attendees. Boasting an exceptional Scientific Programme and educational experience with more than 180 sessions across various tracks, expert speakers will discuss the latest advances and information on trending topics in dermatology.

Find out more via the EADV website: https://www.eadv.org/
References:


